About Cresilon
Cresilon is a company based in New York (United States) founded in 2010. Cresilon has raised $113.35 million across 8 funding rounds from investors including Paulson Investment Company. Cresilon offers products and services including VETIGEL and TRAUMAGEL. Cresilon operates in a competitive market with competitors including Adocia, Imbed Biosciences, Kane Biotech, Alafair Biosciences and Lohmann & Rauscher, among others.
- Headquarter New York, United States
-
Sectors
TechnologyHealthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cresilon, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$113.35 M (USD)
in 8 rounds
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cresilon
Cresilon offers a comprehensive portfolio of products and services, including VETIGEL and TRAUMAGEL.
Gel that stops bleeding in animals within seconds.
Gel for controlling bleeding in human trauma situations.
People of Cresilon
Unlock access to complete
Funding Insights of Cresilon
Cresilon has successfully raised a total of $113.35M across 8 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cresilon
Cresilon has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Paulson Investment Company.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment banking services are provided for small to mid-cap markets.
|
Locked | Locked | Locked |
Investor details for Cresilon
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cresilon
Investment portfolio details for Cresilon
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cresilon
Detailed financials for Cresilon
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cresilon Comparisons
Peer comparison for Cresilon
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cresilon
Cresilon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adocia, Imbed Biosciences, Kane Biotech, Alafair Biosciences and Lohmann & Rauscher, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| Locked | Locked | Locked |
Nanotech-based wound care products are developed and provided.
|
|
| Locked | Locked | Locked |
Therapeutic solutions for biofilm prevention and removal are developed.
|
|
| Locked | Locked | Locked |
Biomaterials and devices for internal wound healing are developed.
|
|
| Locked | Locked | Locked |
Dressing materials and medical devices
|
Detailed competitors of Cresilon
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cresilon
Complete news archive for Cresilon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cresilon
Cresilon was founded in 2010 and raised its 1st funding round 6 years after it was founded.
Cresilon is headquartered in New York, United States. It is registered at New York, New York, United States.
Cresilon is a funded company, having raised a total of $113.35M across 8 funding rounds to date.
Cresilon was founded in 2010 and is based in New York, United States. Operations focus on the medical device sector, where hemostatic gels and devices are developed to control bleeding. VETIGEL, a prescription gel kit, is provided for moderate to severe bleeds in animals only. TRAUMAGEL serves as a temporary device for external traumatic bleeding unsuitable for tourniquets in humans.
Cresilon's top competitors include Imbed Biosciences, Adocia and Kane Biotech.
Cresilon offers VETIGEL and TRAUMAGEL.
Cresilon has 1 investor. Key investors include Paulson Investment Company.